The safety of rofecoxib

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 491-499

  Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cardiovascular; COX 2 inhibitor; Hypertension; Myocardial infarction; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB;

ACUTE KIDNEY FAILURE; ANALGESIC NEPHROPATHY; ANAPHYLAXIS; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENITIS; EPIDEMIOLOGICAL DATA; ESOPHAGITIS; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; INTERSTITIAL NEPHRITIS; INTESTINE OBSTRUCTION; KIDNEY CANCER; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE ACIDOSIS; LUNG EDEMA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SODIUM RETENTION; STROKE; SURGICAL WOUND; THROMBOEMBOLISM; THROMBOSIS; URINARY TRACT CANCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; EPIDEMIOLOGIC STUDIES; KIDNEY; LACTONES; PRODUCT LABELING; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; SAFETY; SULFONES; THROMBOEMBOLISM;

EID: 19444376788     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.491     Document Type: Review

References (54)

1. FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345:433-442.
2. DOUGADOS M et al.: Anti-inflammatory treatment effect of NSAIDs in ankylosing spondilitis (AS) patients with and without concomitant peripheral arthritis. Ann. Rheum. Dis. (2003) 62 (Suppl. 1):21.
3. RUBIN BR, BURTON R, NAVARRA S et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. (2004) 50(2):598-606.
4. MCADAM BF, CATELLA-LAWSON F, MARDINI IA, LAWSON JA, FITZGERALD GA: Systemic biosynthesis of prostacyclin by cyclooxygenase(COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl Acad. Sci. USA (1999) 96:272-277.
5. CATELLA-LAWSON F, McADAM B, MORRISON BW et al.: Effects of specific inhibition of cyclooxygeanse-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. (1999) 289:735-741.
6. CHENG HF, HARRIS RC: Cyclooxygenase, the kidney, and hypertension. Hypertension (2004) 43:525-530.
7. ROSSAT J, MAILLARD M, NUSSBERGER J, BRUNNER HR, BURNIER M: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. (1999) 66:76-84.
8. CHIOLERO A, MAILLARD MP, BURNIER M: Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert Opin. Drug Saf. (2002) 1:45-52.
9. BOMBARDIER C, LAINE L, REICIN A et al.: VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343:1520-1528.
10. RAY WA, STEIN CM, DAUGHERTY JR, HALL K, ARBOGAST PG, GRIFFIN MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 360:1071-1073.
11. JUNI P, NARTEY L, REICHENBACH S, STERCHI R, DIEPPE PA, EGGER M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 364:2021-2029.
12. SOLOMON DH, SCHNEEWEISS S, GLYNN RJ et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 109:2068-2073.
13. MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286:954-959.
14. KONSTAM MA, WEIR MR, REICIN A et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 104:2280-2288.
15. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284:1247-1255.
16. WATSON DJ, YU Q, BOLOGNESE JA, REICIN AS, SIMON TJ: The upper gastrointestinal safety of rofecoxib versus NSAIDs: an updated combined analysis. Curr. Med. Res. Opin. (2004) 20(10):1539-1548.
17. SCHNITZER T, BURMESTER GR, MYSLER E et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364:665-674.
18. MAMDANI M, JUURLINK DN, KOPP A, NAGLIE, G, AUSTIN PC, LAUPACIS A: Gastrointestinal bleeding after the introduction of COX-2 inhibitors: ecological study. Br. Med. J. (2004) 328:1415-1416.
19. LUGARDON S, LAPEYRE-MESTRE M, MONTASTRUC JL: Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur. J. Clin. Pharmacol. (2004) 60:673-677.
20. QUIRALTE J, DELGADO J, SAENZ DE SAN PEDRO B et al.: Safety of the new selective cyclooxygenase Type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann. Allergy Asthma Immunol. (2004) 93(4):360-364.
21. WOESSNER KM, SIMON RA, STEVENSON DD: Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. (2004) 93(4):339-344.
22. MARTIN-GARCIA C, HINOJOSA M, BERGES P et al.: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest (2002) 121(6):1812-1817.
23. PHAN O, MEIER P, BURNIER M: Are cyclooxygenase-2-selective inhibitors safe for the kidneys? Joint Bone Spine (2003) 70:237-241.
24. BRATER DC, HARRIS C, REDFERN JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am. J. Nephrol. (2001) 21:1-15.
25. SCHWARTZ JI, VANDORMAEL K, MALICE MP et al.: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal salt diet. Clin. Pharmacol. Ther. (2002) 72:50-61
26. SWAN SK, RUDY DW, LASSETER KC et al.: Effect of cyclo-oxygenase-2 inhibition on renal function in elderly persons receiving a low salt diet. Ann. Intern. Med. (2000) 133:1-9.
27. GERTZ BJ, KRUPA D, BOLOGNESE JA, SPERLING RS, REICIN A: A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr. Med. Res. Opin. (2002) 18:82-91.
28. MAMDANI M, JUURLINK DN, LEE DS et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet (2004) 363:1751-1756.
29. WHELTON A, MAURATH CJ, VERBURG KM, GEIS GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am. J. Ther. (2000) 7:159-175.
30. Australian Cox-2 Specific Inhibitor Prescribing Group: Considerations for the safe use and prescribing of Cox-2-specific inhibitors. Med. J. Aust. (2002) 176:332-334.
31. WHELTON A, WHITE WB, BELLO AE, PUMA JA, FORT JG: Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. (2002) 90:959-963.
32. POPE JE, ANDERSON JJ, FELSON DT: A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch. Intern. Med. (1993) 153:477-484.
33. HOCHERL K, ENDEMANN D, GROBECKER HF, KURTZ A: Cyclooxygenase-2 inhibition increases blood pressure in rats. Br. J. Pharmacol. (2002) 136:1117-1126.
34. QI Z, HAO CM, LANGENBACH RI et al.: Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. (2002) 110:61-69.
35. WHITE WB, KENT J, TAYLOR A, VERBURG KM, LEFKOWITH JB, WHELTON A: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension (2002) 39:929-934.
36. SOWERS JR, WHITE WB, PITT B et al.: The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus. Arch. Int. Med. (2005) 165(2):161-168.
37. MORGAN TO, ANDERSON A, BERTRAM D: Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am. J. Hypertens. (2000) 13:1161-1167
38. SOLOMON DH, SCHNEEWEISS S, LEVIN R, AVORN J: Relationship between COX-2 specific inhibitors and hypertension. Hypertension (2004) 44:140-145.
39. The Allhat Collaborative Research Group: Major outcomes in high-risk hypetrensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA (2002) 288:2981-2997.
40. JULIUS S, KJELDSEN SE, WEBER M et al.: VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 363:2022-2031.
41. FITZGERALD GA: COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. (2003) 2:879-890.
42. SOLOMON DH, GLYNN RJ, LEVIN R, AVORN J: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Int. Med. (2002) 162:1099-1104.
43. RAHME E, PILOTE L, LELORIER J: Association between naproxen use and protection against acute myocardial infarction. Arch. Int. Med. (2002) 162:1111-1115.
44. WATSON DJ, RHODES T, CAI B, GUESS HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Int. Med. (2002) 162:1105-1110.
45. REICIN A, SHAPIRO D, SPERLING RS, BARR E, YU O: Comparison of cardiovascular thrombotic event in patients with osteoarthritis treated with rofecoxib versus non-selective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am. J. Cardiol. (2002) 89:204-209
46. BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352: ahead of publication.
47. FARKOUH ME, KIRSHNER H, HARRINGTON RA et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 364:675-684.
48. OTT E, NUSSMEIER NA, DUKE PC et al.: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. (2003) 125:1481-1492.
49. NUSSMEIER NA, WHELTON AA, BROWN MT et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. (2005) 352: ahead of publication.
50. SOLOMON SD, McMURRAY JJV, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. (2005) 352: ahead of publication.
51. SCHONBECK U, SUKHOVA GK, GRABER P, COULTER S, LIBBY P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. (1999) 155:1281-1291.
52. CHENEVARD R, HÜRLIMANN D, BÉCHIR M et al.: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation (2003) 107:405-409.
53. BULUT D, LIAGHAT S, HANEFELD C, KOLL R, MIEBACH T, MUGGE A: Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J. Hypertens. (2003) 21:1663-1667.
54. GRAHAM DJ, CAMPEN D, HUI R et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet (2005) 265:475-481.